Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Phase 2Vaccine
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 is one of 71 biologic programs targeting Chronic Lymphocytic Leukemia. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
GGeoVax, Inc.
Phase 2
Tricor
JJagotec
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Blood Cancer1 trial
COVID-191 trial
Chronic Lymphocytic Leukemia1 trial
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Recruiting·—·Phase 2·NCT05672355·80 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 2[1]
- Company
- GGeoVax, Inc.